市场调查报告书
商品编码
1439662
血液浓缩器 - 全球市场回顾、竞争格局、市场预测 (2030)Hemoconcentrators - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
全球血液浓缩器市场规模预计到 2023 年将达到 1,163 万美元,到 2030 年将达到 1,404 万美元,2024-2030 年预测期间复合年增长率为 3.24%。 由于心血管疾病负担的增加、老年人口的增加、政府的举措增多以及对提高血液浓缩器的安全性、可用性和易用性的日益关注等因素,血液浓缩器市场预计将增长。预测期内( 2024-2030)的收入成长。
血液浓缩器市场动态
血液浓缩器市场的显着驱动因素之一是心血管疾病盛行率的上升。
根据世界卫生组织 (WHO) (2022) 的数据,心血管疾病被认为是世界上最主要的死亡原因,每年影响约 1790 万人的生命。 需要搭桥手术的心血管疾病主要包括冠状动脉疾病、主动脉瓣狭窄、水肿等疾病。
世界心臟联盟(2019)的另一项研究估计,到 2030 年,全球将有超过 2,300 万人受到心血管疾病的影响。
心血管疾病盛行率的增加可能与心血管疾病危险因子的增加有关,例如不健康的生活方式、吸烟、高血压、糖尿病、饮酒和肥胖。
例如,根据健康指标与评估研究所(2023)的数据,2019 年全球吸烟者数量增加至 11 亿,其中 90% 的新吸烟者在 25 岁时就开始上瘾。
世界卫生组织 (2023) 的另一项有趣统计数据指出,从 1990 年到 2019 年,高血压患者人数翻了一番,达到 12.8 亿人。
上述风险因素的增加将增加未来几年进行搭桥手术的需求,进而增加对血液浓缩器的需求。
此外,老年人口的增加更容易患心血管疾病,预计将进一步加速血液浓缩器市场的成长。 根据世界卫生组织(2023)提供的数据,2020年,全球约有10亿人年龄在60岁或以上。 上述数据预测,到2050年,60岁以上老年人口将翻一番,达到约21亿人。 此外,预计 2020 年至 2050 年间,80 岁及以上的人口将增加两倍,达到 4.26 亿人。
因此,上述因素预计将加速血液浓缩器市场的成长。
然而,缺乏熟练的专业人员和手术期间的併发症可能是血液浓缩器市场的限制因素。
血液浓缩器市场预计将在最初几个月受到影响,因为COVID-19 大流行导致封锁、边境关闭以及与血液浓缩器市场相关的活动(如製造、供应、进口和出口)的其他中断。对增长产生轻微负面影响。 此外,由于担心 SARS-CoV-2 病毒(COVID-19 的病原体)的传播以及大流行的不确定性,世界上许多国家都关闭了除紧急情况外的门诊手术中心 (ASC)。被迫。 然而,包括医疗产业在内的各行业活动的恢復正在推动血液浓缩器市场的发展,预计将在 2024 年至 2030 年的预测期内推动成长。
血液浓缩器细分市场分析
在血液浓缩器市场的产品类型细分中,儿科血液浓缩器类别在 2022 年占最高收入占有率,达到 71%。
患有心臟病的儿科患者数量不断增加是儿科血液浓缩机增长的主要原因。 根据 NHS (2022) 的数据,英国每 100 个婴儿中就有 1 个出生时患有先天性心臟病。
根据美国疾病管制与预防中心 (2022) 的数据,大约四分之一的出生时患有心臟缺陷的婴儿患有严重的先天性心臟病 (CHD)。
本报告研究和分析了全球血液浓缩器市场,提供市场规模和预测、驱动因素和挑战、公司和产品概况等。
Hemoconcentrators Market By Product Type (Pediatric Hemoconcentrators And Adult Hemoconcentrators), By End-User (Hospitals And Ambulatory Surgical Centres), and by geography is estimated to register a growth at a remarkable CAGR forecast during 2024-2030 owing to a surge in the cases of cardiovascular diseases and growing burden of geriatric population globally
The global hemoconcentrators market was valued at USD 11.63 million in 2023, growing at a CAGR of 3.24% during the forecast period from 2024 to 2030 to reach USD 14.04 million by 2030. The hemoconcentrators market is slated to witness growth owing to factors such as the rising burden of cardiovascular disorders, the rising geriatric population, the increasing number of government initiatives by countries, and the growing focus on improving the safety, affordability, and usability of hemoconcentrators is expected to result in appreciable revenue growth in the hemoconcentrators market during the forecast period (2024-2030).
Hemoconcentrators Market Dynamics:
One of the noteworthy drivers of the hemoconcentrators market is the rise in the prevalence of cardiovascular diseases.
As per the data provided by the World Health Organization (WHO) 2022, cardiovascular disorders are considered the leading cause of death worldwide affecting about 17.9 million lives every year. Cardiovascular diseases requiring bypass surgeries mainly include disorders such as coronary artery disease, aortic stenosis, and edema, among others.
In another study by the World Heart Federation in the year 2019, it had estimated that more than 23 million lives will be affected globally owing to cardiovascular disorders by the year 2030.
The increase in the rates of cardiovascular diseases can be linked to an increase in the risk factors for cardiovascular diseases such as unhealthy lifestyle, tobacco usage, hypertension, diabetes, alcohol consumption, obesity, and others.
For instance, according to the Institute for Health Metrics and Evaluation (2023), the number of smokers worldwide increased to 1.1 billion in 2019, where 90% of all new smokers became addicted by the age of 25.
Another interesting statistic by the WHO (2023), quoted that the number of people living with hypertension doubled to 1.28 billion from 1990-2019.
The increase in the abovementioned risk factors will increase the demand for more bypass surgeries to take place in the upcoming years, thus raising the demand for hemoconcentrators.
Additionally, the rising geriatric population prone to the development of cardiovascular diseases is further going to accelerate the growth of the hemoconcentrators market. According to the data provided by the WHO (2023), in 2020, about one billion people across the world were over the age of 60. The source mentioned above added by stating that by 2050, the elderly population aged 60 and above is expected to double in number representing about 2.1 billion people. Also, people in the age group of 80 and above are estimated to triple between 2020 and 2050 to reach 426 million.
Thereby, the above-mentioned factors are expected to accelerate the growth of the hemoconcentrators market.
However, the dearth of skilled professionals and complications during surgery may act as restraining factors for the hemoconcentrators market.
The COVID-19 pandemic had a slightly negative impact on the market growth of hemoconcentrators during the initial few months owing to the lockdown impositions, border closures, and others leading to the disruption in the manufacturing, supply, import, export, and other related activities of the hemoconcentrators market. Also, owing to the fear of the spread of the SARS-CoV-2 virus which is the causative agent for COVID-19, and uncertainties revolving around the pandemic, many countries across the world were forced to close down ambulatory surgical centers (ASCs) except in case of emergencies. However, the resumption of activities across industries including the healthcare sector has been uplifting the hemoconcentrators market and will drive growth during the forecast period from 2024-2030.
Hemoconcentrators Market Segment Analysis:
Hemoconcentrators Market by Product Type (Pediatric Hemoconcentrators and Adult Hemoconcentrators), End-user (Hospitals and Ambulatory Surgical Centres), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product type segment of the hemoconcentrators market, the pediatric hemoconcentrators category held the highest revenue share of 71% in 2022.
The increasing number of pediatric patients with heart diseases is the main reason responsible for the growth of pediatric hemoconcentrators. According to NHS 2022, one in a hundred babies are born with congenital heart disease in the UK.
As per the Centers for Disease Control and Prevention, 2022, about 1 in 4 babies born with a heart defect have a critical congenital heart defect (CHD).
The increasing importance of pediatric coronary artery bypass surgery (PCABS) for congenital heart disease in infants and children undergoing modern cardiac surgical procedures, because of its life-saving potential in unsuccessful coronary transfer operations is going to increase the demand for pediatric hemoconcentrators.
Due to the small size and low weight of pediatric patients among other factors, performing bypass surgery in infants and neonates is complicated. Pediatric hemoconcentrators help in reducing inflammatory cytokines and correcting electrolyte and acid-base imbalances, limit early postoperative RBCs transfusions, reduces swelling of the heart, and facilitate the closing of surgical incision for better outcome of pediatric cardiac surgery.
For example, CAPIOX® HC05 Hemoconcentrators by Terumo Corporation is a type of pediatric Hemoconcentrator that efficiently concentrates blood using a polysulfone membrane material at a high ultrafiltration rate.
Therefore, owing to the above-mentioned factors the pediatric hemoconcentrators category is expected to witness substantial growth in the overall hemoconcentrators market during the given forecast period.
North America is expected to dominate the overall Hemoconcentrators Market:
Among all the regions, North America held the largest share of 45% in the hemoconcentrators market in 2022.
This domination is owing to the surging prevalence of cardiovascular disorders such as heart failure, congenital heart disease, hypertension, and others, the growing government initiatives in the cardiovascular sector in the United States, and the presence of key players in the region is expected to propel the overall market growth.
According to the latest study conducted by the Centres for Disease Control and Prevention (CDC), one person dies every 34 seconds in the United States from cardiovascular disease. Also, as per the same source, about 697,000 people in the United States died from heart disease in 2020, in the United States and about 20.1 million adults aged 20 and older had coronary artery disease (CAD). The mortality rate can be controlled by treating or managing the disease through surgical procedures such as cardiac bypass surgery, ultimately increasing the demand for hemoconcentrators.
As per the above-mentioned source, congenital heart defects are the most common type of birth defect in the United States, affecting nearly 1% (about 40,000) of births per year. The American Heart Association projected that by 2035, more than 130 million US adults will have some type of heart disease.
Moreover, the increasing prevalence of risk factors for cardiovascular diseases such as hypertension, obesity, age, arteriosclerosis, and others will in turn drive the market for hemoconcentrators. As per the source, Million Heart, 2022, high blood pressure is the most prevalent heart disease in the US, as almost half of the population had been diagnosed with hypertension, in 2020.
Therefore, the above-mentioned factors are going to bolster the North America hemoconcentrators markets.
Hemoconcentrators Market Key Players:
Some of the key market players operating in the Hemoconcentrators market include Getinge AB, LivaNova PLC, Braile Biomedica, Terumo Corporation, MEDICA S.P.A., Andocor, NIPRO, STERIS, Chalice Medical Ltd., and others.
Recent Developmental Activities in the Hemoconcentrators Market:
In June 2022, STERIS plc completed the acquisition of Cantel Medical which was the parent company of Medivators Inc. and Minntech, leading manufacturers of hemoconcentrators.
Key Takeaways from the Hemoconcentrators Market Report Study
Market size analysis for current hemoconcentrators market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the hemoconcentrators market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years.
Key companies dominating the global hemoconcentrators market.
Various opportunities available for the other competitor in the hemoconcentrators market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current hemoconcentrators market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for hemoconcentrators market growth in the coming future?
Target Audience who can be benefited from this Hemoconcentrators Market Report Study
Hemoconcentrators providers
Research organizations and consulting companies
Hemoconcentrators -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in hemoconcentrators
Various end users who want to know more about the hemoconcentrators market and the latest technological developments in the hemoconcentrators market.
Frequently Asked Questions for the Hemoconcentrators Market:
A hemoconcentrator is an ultrafiltration device consisting of semipermeable membrane fibers that remove plasma water and solutes. Blood passes through fibers of a microporous membrane, and since the hydrostatic pressure inside the fibers is higher than outside, effluent fluid can pass through the membrane and be drained.
The global hemoconcentrators market was valued at USD 11.63 million in 2023, growing at a CAGR of 3.24% during the forecast period from 2024 to 2030 to reach USD 14.04 million by 2030.
The hemoconcentrators market is expected to grow significantly owing to factors such as the rising burden of cardiovascular disorders, the rising geriatric population, and the increasing number of government initiatives by countries, among others during the given forecast period (2024-2030).
Some of the key market players operating in the hemoconcentrators market include Getinge AB, LivaNova PLC, Braile Biomedica, Terumo Corporation, MEDICA S.P.A., Andocor, NIPRO, STERIS, Chalice Medical Ltd., and others.
North America is expected to dominate the overall hemoconcentrators market during the forecast period, 2024 to 2030. This can be ascribed to the presence of a large number of people suffering from cardiovascular diseases along with the rising geriatric population in the region. In addition, it is a highly potent market in terms of technological developments and launches along with the presence of key market players among other factors in the region.